Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Colombia S.A.S. and Astrazeneca Colombia S.A.S. have entered into an exclusive licensing agreement for the commercialization of Astrazeneca’s drug Pulmicort Respules. Under the terms of the agreement, Astrazeneca remains the holder of the registration for Pulmicort Respules and will be responsible for manufacturing and supplying the drug. Glenmark will be responsible for commercialization of Pulmicort Respules in the Colombian market.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
